IGHVII-60-1: A Potential Drug Target and Biomarker (G28361)

Target Name: IGHVII-60-1

NCBI ID: G28361

IGHVII-60-1

Other Name(s): Immunoglobulin heavy variable (II)-60-1 (pseudogene) | 4-60.1P | immunoglobulin heavy variable (II)-60-1 (pseudogene) | IGHVII601

IGHVII-60-1: A Potential Drug Target and Biomarker

IGHVII-60-1 (Immunoglobulin heavy variable (II)-60-1 (pseudogene)) is a glycoprotein that is expressed in various tissues of the body, including the liver, spleen, and kidneys. It is a member of the Ig family of antibodies and is characterized by its heavy chain consisting of four constant (C) regions and one variable (V) region.

IGHVII-60-1 has been identified as a potential drug target or biomarker due to its unique structure and Expression. The IGHVII-60-1 molecule has a length of 186 amino acids and a calculated molecular weight of 21 kDa. It consists of two heavy chains and one light chain. The heavy chains contain four constant regions (C1-C4) and one variable region (V).

The IGHVII-60-1 molecule is a glycoprotein, which means it is composed of both protein and carbohydrate components. The protein component of IGHVII-60-1 consists of two heavy chains and one light chain. The heavy chains contain four constant regions ( C1-C4) and one variable region (V). The variable region contains the variable regions (Ig variable region) that give the molecule its unique structure.

One of the key features of IGHVII-60-1 is its large size, which allows it to interact with various cell surface receptors and other proteins. Its large size also makes it a potential biomarker for certain diseases.

IGHVII-60-1 has been shown to play a role in various biological processes in the body. For example, it is involved in the immune response, which is a critical function of the body's immune system. It is also involved in the regulation of inflammation, which is important for maintaining the health and function of the body.

In addition to its role in the immune response and inflammation, IGHVII-60-1 has also been shown to play a role in the regulation of cell signaling. This is important for the proper functioning of cells and is potentially relevant to the development of various diseases.

IGHVII-60-1 is also a potential drug target due to its unique structure and Expression. The IGHVII-60-1 molecule has a large size and a unique structure, which makes it an attractive target for drug development. Additionally, its role in Various biological processes in the body make it a valuable biomarker for the development of diseases.

In conclusion, IGHVII-60-1 (Immunoglobulin heavy variable (II)-60-1 (pseudogene)) is a glycoprotein that is expressed in various tissues of the body and has been identified as a potential drug target or biomarker. Its large size and unique structure make it an attractive target for drug development and its role in various biological processes in the body make it a valuable biomarker for the development of diseases. Further research is needed to fully understand the role of IGHVII-60-1 in the immune response and inflammation, as well as its potential as a drug target.

Protein Name: Immunoglobulin Heavy Variable (II)-60-1 (pseudogene)

The "IGHVII-60-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHVII-60-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets